GLOBAL 15 countries Current AMR Commercially Organism ICU, long-term Susceptibility S. pneumoniae n/a surveillance surveillance funded care facilities testing of key H. influenzae and outpatient respiratory tract M. catarrhalis publications 206 settings pathogens against commonly prescribed antimicrobial agents 203, Principally Current AMR Commercially Organism Hospital Internet-based All clinically n/a Website; 204, 207 US, but also surveillance funded by centres/ data resource of encountered conferences Canada, (passive Eurofins laboratories in vitro bacterial and Europe, surveillance antimicrobial pathogens (597 Australia and of susceptibility taxa) and publications; New resistance data antimicrobial data not Zealand. patterns) agents (119). publicly Operated in Primary source available Australia of antimicrobial from susceptibility data for the US however, was FDA not considered viable and data was purchased by the Australian Society for
GLOBAL surveillance 206 15 countries Current AMR surveillance Commercially funded Organism ICU, long-term care facilities and outpatient settings Susceptibility testing of key respiratory tract pathogens against commonly prescribed antimicrobial agents S. pneumoniae H. influenzae M. catarrhalis n/a publications 203, 204, 207 Principally US, but also Canada, Europe, Australia and New Zealand. Operated in Australia from however, was not considered viable and data was purchased by the Australian Society for Current AMR surveillance (passive surveillance of resistance patterns) Commercially funded by Eurofins Organism Hospital centres/ laboratories Internet-based data resource of in vitro antimicrobial susceptibility data All clinically encountered bacterial pathogens (597 taxa) and antimicrobial agents (119). Primary source of antimicrobial susceptibility data for the US FDA n/a Website; conferences and publications; data not publicly available
National-surveillance-and-reporting-of-antimicrobial-resistance-and-antibiotic-usage-for-human-health-in-Australia.docx